Showing results (841-850 of 908) with videos related to

Sort By:
Pageof 91
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2018
Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated VasculitisAlvise Berti, Roscoe Warner, Kent Johnson, et al.
Immunity|October 1, 2020
In Situ Maturation and Tissue Adaptation of Type 2 Innate Lymphoid Cell ProgenitorsPatrice Zeis, Mi Lian, Xiying Fan, et al.
Cell|January 14, 2023
Immunity to the microbiota promotes sensory neuron regenerationMichel Enamorado, Warakorn Kulalert, Seong-Ji Han, et al.
Archives of Environmental Health|June 23, 2006
Polycyclic aromatic hydrocarbon-DNA adducts and breast cancer: a pooled analysisMarilie D Gammon, Sharon K Sagiv, Sybil M Eng, et al.
The Journal of Infectious Diseases|July 27, 2025
Clinical and environmental surveillance of poliovirus type 2 outbreak using a novel specific real-time quantitative PCR assay, Israel, 2022-2023Itay Bar-Or, Merav Weil, Hadar Assraf, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 14, 2018
Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failureZhaochun Chen, Giacomo Diaz, Teresa Pollicino, et al.
Journal of Hepatology|April 4, 2022
Metformin treatment rescues CD8<sup>+</sup> T-cell response to immune checkpoint inhibitor therapy in mice with NAFLDSimon Wabitsch, Justin D McCallen, Olena Kamenyeva, et al.
Science Immunology|October 14, 2022
Resident T<sub>H</sub>2 cells orchestrate adipose tissue remodeling at a site adjacent to infectionAgnieszka M Kabat, Alexandra Hackl, David E Sanin, et al.
Blood Cancer Journal|November 13, 2023
Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort studyAllison M Bock, Jennifer J Gile, Melissa C Larson, et al.
Annals of Hematology|June 4, 2020
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomesWilliam J Archibald, Kari G Rabe, Brian F Kabat, et al.
Pageof 91